Literature DB >> 9048520

Perineal powder exposure and the risk of ovarian cancer.

L S Cook1, M L Kamb, N S Weiss.   

Abstract

This case-control study evaluated the risk of epithelial ovarian cancer associated with genital exposure to various forms of powder application. Cases included all women aged 20-79 years in three counties of western Washington who were diagnosed with borderline or invasive ovarian cancer from 1986 through 1988; 64.3% of eligible cases were interviewed. A sample of similarly aged women who lived in these counties, identified by random digit dialing, served as controls. The overall response among control women was 68.0%. Information on powder application and other potential risk factors was ascertained during the in-person interview. Overall, ovarian cancer cases (n = 313) were more likely than controls (n = 422) to ever have used powder (age-adjusted relative risk (RR) = 1.5, 95% confidence interval (CI) 1.1-2.0). After adjustment for age and other methods of genital powder application (none vs. any), an elevated relative risk of ovarian cancer was noted only for women with a history of perineal dusting (RR = 1.6, 95% CI 1.1-2.3) or use of genital deodorant spray (RR = 1.9, 95% CI 1.1-3.1). These results offer support for the hypothesis, raised by prior epidemiologic studies, that powder exposure from perineal dusting contributes to the development of ovarian cancer, and they suggest that use of genital deodorant sprays may do so as well. Limitations of the present study include the fairly low proportion of eligible women who participated and the potential differential recall of powder usage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9048520     DOI: 10.1093/oxfordjournals.aje.a009128

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  17 in total

1.  Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies.

Authors:  Simone P Pinheiro; Susan E Hankinson; Shelley S Tworoger; Bernard A Rosner; John R McKolanis; Olivera J Finn; Daniel W Cramer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

2.  Douching, Talc Use, and Risk of Ovarian Cancer.

Authors:  Nicole L Gonzalez; Katie M O'Brien; Aimee A D'Aloisio; Dale P Sandler; Clarice R Weinberg
Journal:  Epidemiology       Date:  2016-11       Impact factor: 4.822

3.  Use of fertility drugs and risk of ovarian cancer: results from a U.S.-based case-control study.

Authors:  Michelle L Kurta; Kirsten B Moysich; Joel L Weissfeld; Ada O Youk; Clareann H Bunker; Robert P Edwards; Francesmary Modugno; Roberta B Ness; Brenda Diergaarde
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-15       Impact factor: 4.254

4.  Body Powder and Ovarian Cancer Risk-What Is the Role of Recall Bias?

Authors:  Britton Trabert
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-10       Impact factor: 4.254

Review 5.  Current understanding of risk factors for ovarian cancer.

Authors:  Thanasak Sueblinvong; Michael E Carney
Journal:  Curr Treat Options Oncol       Date:  2009-07-15

Review 6.  Perineal talc use and ovarian cancer: a critical review.

Authors:  Joshua E Muscat; Michael S Huncharek
Journal:  Eur J Cancer Prev       Date:  2008-04       Impact factor: 2.497

7.  Talc use, variants of the GSTM1, GSTT1, and NAT2 genes, and risk of epithelial ovarian cancer.

Authors:  Margaret A Gates; Shelley S Tworoger; Kathryn L Terry; Linda Titus-Ernstoff; Bernard Rosner; Immaculata De Vivo; Daniel W Cramer; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

8.  Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls.

Authors:  Kathryn L Terry; Stalo Karageorgi; Yurii B Shvetsov; Melissa A Merritt; Galina Lurie; Pamela J Thompson; Michael E Carney; Rachel Palmieri Weber; Lucy Akushevich; Wei-Hsuan Lo-Ciganic; Kara Cushing-Haugen; Weiva Sieh; Kirsten Moysich; Jennifer A Doherty; Christina M Nagle; Andrew Berchuck; Celeste L Pearce; Malcolm Pike; Roberta B Ness; Penelope M Webb; Mary Anne Rossing; Joellen Schildkraut; Harvey Risch; Marc T Goodman
Journal:  Cancer Prev Res (Phila)       Date:  2013-06-12

9.  Pathogenesis of serous, extra-uterine Müllerian epithelial cancer and therapeutic implications.

Authors:  Louis Dubeau
Journal:  Transl Cancer Res       Date:  2015-02       Impact factor: 1.241

10.  Risk factors for epithelial ovarian cancer by histologic subtype.

Authors:  Margaret A Gates; Bernard A Rosner; Jonathan L Hecht; Shelley S Tworoger
Journal:  Am J Epidemiol       Date:  2009-11-12       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.